Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib in advanced solid tumors
NCT03507543Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of senaparib in solid tumor (advanced stage), breast cancer, ovarian cancer and 2 more, sponsored by IMPACT Therapeutics. Primary endpoints: Adverse Events and Maximum Tolerated Dose at 28 days. Started Feb 2017; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerprostate cancer (PCa)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03507543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507543.